Fundamentals of JNJ Speak For Themselves: Analyst
Johnson & Johnson (JNJ) reported new data on its one-shot vaccine.
It doesn't require excessively low temperatures to keep in storage and reached an overall efficacy rate of 66% in the 44,000 person study of patients with moderate to severe forms of COVID-19.
The trial also indicated an 85% rate of protection against patients with more severe forms and a 57% rate of efficacy against the new strain of the virus recently identified in South Africa.
Jeff Marks, senior portfolio analyst with Jim Cramer's Action Alerts PLUS, discusses Johnson & Johnson (JNJ) .
Curious about what Jim Cramer and his team at Action Alerts PLUS are watching in the markets? Watch Cramer's exclusive members-only Daily Rundown show on Action Alerts PLUS following TheStreet Live.
Recap TheStreet Live: Everything Moving the Markets Friday
Latest Videos From TheStreet and Jim Cramer:
